Table 5 Linear mixed models of rash, weight loss, and mouth sores/ulcers
Rasha | Weight lossb | Mouth sores/ulcersc | ||||
|---|---|---|---|---|---|---|
Effect | Estimate (SE) | P-value | Estimate (SE) | P-value | Estimate (SE) | P-value |
Intercept | 1.38 (1.065) | 0.198 | 5.051 (2.337) | 0.032 | 5.661 (1.795) | 0.002 |
Time (months) since diagnosis | −0.01 (0.007) | 0.299 | − 0.05 (0.016) | 0.002 | − 0.06 (0.011) | < 0.0001 |
Treatment: cetuximab±RT (vs. cisplatin±RT) | 1.45 (0.235) | < 0.0001 | 0.12 (0.511) | 0.817 | −0.24 (0.412) | 0.567 |
Treatment* time since diagnosis | −0.06 (0.023) | 0.013 | −0.04 (0.047) | 0.356 | 0.03 (0.036) | 0.375 |
Age at diagnosis | −0.03 (0.009) | 0.005 | −0.05 (0.021) | 0.036 | −0.05 (0.015) | 0.001 |
Male (vs. female) | −0.11 (0.179) | 0.541 | − 0.31 (0.434) | 0.480 | −0.59 (0.291) | 0.044 |
White (vs. minority/unknown) | −0.01 (0.164) | 0.946 | −0.41 (0.387) | 0.291 | 0.35 (0.268) | 0.188 |
Impaired composite performance status (vs. not impaired) | 0.29 (0.314) | 0.363 | 0.88 (0.713) | 0.216 | −0.53 (0.506) | 0.291 |
Weighted index of comorbid conditions | −0.01 (0.085) | 0.896 | 0.02 (0.222) | 0.927 | −0.06 (0.141) | 0.697 |
Smoking status: current or past (vs. never/unknown/undocumented) | −0.20 (0.202) | 0.334 | 0.24 (0.488) | 0.628 | 0.04 (0.332) | 0.912 |
Alcohol status | – | 0.061 | – | 0.361 | – | 0.074 |
Current or past abuse (vs. never/unknown/undocumented) | 0.49 (0.212) | 0.020 | 0.61 (0.506) | 0.227 | 0.72 (0.346) | 0.037 |
Current or past use (vs. never/unknown/undocumented) | 0.28 (0.174) | 0.105 | −0.02 (0.420) | 0.970 | 0.09 (0.283) | 0.750 |
Stage at start: Stage III (vs. Stage IV) | −0.04 (0.154) | 0.773 | −0.24 (0.353) | 0.493 | 0.10 (0.250) | 0.699 |
Oral (vs. non-oral) | −0.04 (0.414) | 0.922 | −0.55 (1.017) | 0.588 | 0.82 (0.699) | 0.243 |
Pharynx (vs. non-pharynx) | −0.19 (0.404) | 0.637 | −0.32 (0.923) | 0.733 | 0.66 (0.682) | 0.336 |
Larynx (vs. non-larynx) | −0.20 (0.428) | 0.639 | −0.09 (0.963) | 0.929 | −0.41 (0.719) | 0.567 |
HPV test results (positive vs. non-positive) | 0.14 (0.426) | 0.740 | 0.54 (1.007) | 0.591 | 1.52 (0.712) | 0.033 |
P16 test results (positive vs. non-positive) | 0.05 (0.181) | 0.776 | 0.06 (0.512) | 0.911 | −0.24 (0.293) | 0.414 |
Feeding tube placement (vs. not placed) | −0.05 (0.156) | 0.739 | −0.14 (0.373) | 0.707 | 0.42 (0.254) | 0.099 |
BMI | 0.02 (0.012) | 0.222 | −0.02 (0.028) | 0.583 | −0.01 (0.020) | 0.777 |
Insurance | – | 0.042 | – | 0.475 | – | 0.375 |
Only public (vs. only private) | 0.07 (0.209) | 0.738 | 0.61 (0.500) | 0.226 | 0.39 (0.343) | 0.261 |
Both public and private (vs. only private) | 0.53 (0.196) | 0.008 | 0.65 (0.459) | 0.156 | 0.42 (0.320) | 0.185 |
Other/unknown/undocumented (vs. only private) | 0.19 (0.496) | 0.700 | 0.63 (1.235) | 0.612 | 1.03 (0.833) | 0.215 |
US Region South (vs. non-South) | 0.25 (0.706) | 0.727 | 0.86 (1.428) | 0.545 | −1.14 (1.225) | 0.354 |